SURVYR

SLS

SELLAS Life Sciences Group, Inc.
$10.38
−$1.79 (14.71%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-28%+158%+345%+532%+719%Oct 2025Oct 2026Apr 202652w high $15.8852w low $1.39
SLSSPY
Wall St. Highest PT $35.00 (+237.2%) Wall St. Avg PT $32.50 (+213.1%)
$1$10$19$27$36POC $5Hi $35Avg $32
Underwater Drawdown %Max DD -35.4%Current -32.9%
0.0%-35.4%
Relative Strength vs SPY+421.1% vs SPYOutperforming
+790%0%-790%
1W
−$1.70 (14.07%)
1M
−$1.21 (10.44%)
3M
+$0.28 (2.77%)
6M
+$5.71 (122.27%)
YTD
+$6.61 (175.33%)
1Y
+$8.38 (419.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$10.38
Average target$32.50
+$22.12 (+213.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$30.00
Median$32.50
High$35.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-03-12 · Maxim Group reiterated Buy on SLS
Reiterated
2025-07-16 · Maxim Group reiterated Buy on SLS
Reiterated
2023-11-22 · Cantor Fitzgerald reiterated Overweight on SLS
Reiterated
2023-09-07 · Cantor Fitzgerald reiterated Overweight on SLS
Reiterated
2022-11-15 · Alliance Global Partners reiterated Buy on SLS
Reiterated
2022-06-28 · Cantor Fitzgerald reiterated Overweight on SLS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.4B
P/E (next 12 months, estimated)-120.8
52-week range$1.39 – $15.88
Dividend yieldNo dividend
Average analyst price target$32.50 (+213%)

What they do

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for SLS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

SLS earningsNext report in 13 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Time not confirmed
EPS consensus-$0.05 range -$0.05–-$0.05
Revenue consensus$0 1 analysts
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.05est -$0.04−11.1%Below estimates
Mar 19, 2026-$0.05est -$0.06+21.1%Above estimates
Nov 12, 2025-$0.06est -$0.08+21.7%Above estimates
Aug 12, 2025-$0.07est -$0.08+8.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:15:24 ET
24-0824-1125-0325-0525-0825-1126-0326-08-0.170.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Why Are Nasdaq Futures Falling Premarket? CRWV, NBIS, TSLA, SPCX, MU, ASTS, NFLX, SLS Stocks In Focus
Stocktwits · Oct 20
SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years
Stocktwits · Oct 20
SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News
Stocktwits · Oct 19
Why Are Nasdaq Futures Soaring Premarket? NBIS, MU, TSLA, SPCX, ASTS, SLS Stocks In Focus
Stocktwits · Oct 19
SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps
Stocktwits · Oct 18
Rating changes
Reiterated
2026-03-12 · Maxim Group reiterated Buy on SLS
Reiterated
2025-07-16 · Maxim Group reiterated Buy on SLS
Reiterated
2023-11-22 · Cantor Fitzgerald reiterated Overweight on SLS
Reiterated
2023-09-07 · Cantor Fitzgerald reiterated Overweight on SLS
Reiterated
2022-11-15 · Alliance Global Partners reiterated Buy on SLS
Reiterated
2022-06-28 · Cantor Fitzgerald reiterated Overweight on SLS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 12:15:24 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026